Covid-19 roundup: BAR­DA pumps $60M more in­to SAB treat­ment; EMA to de­cide on boost­ers next month

SAB Bio­ther­a­peu­tics said Thurs­day the US fed­er­al gov­ern­ment is pro­vid­ing it with an ad­di­tion­al $60.5 mil­lion, and more than $200 mil­lion in to­tal, to ad­vance its in­tra­venous poly­clon­al an­ti­body can­di­date for the treat­ment of Covid-19.

The treat­ment, known as SAB-185, is cur­rent­ly in a Phase II/III tri­al in non-hos­pi­tal­ized pa­tients with mild-mod­er­ate Covid-19 in­fec­tions at risk for dis­ease pro­gres­sion. It looks to be the third an­ti­body treat­ment for Covid-19 au­tho­rized in the US, fol­low­ing those from Re­gen­eron, Eli Lil­ly and GSK/Vir Biotech­nol­o­gy (which the fed­er­al gov­ern­ment is not dis­trib­ut­ing).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.